 |
| NeuRx DPS--Courtesy of Synapse |
Cleveland-based Synapse Medical pulled in $2.4 million from Ohio Third Frontier, the state's tech-based economic development initiative, to help advance the next generation of the company's NeuRx diaphragm pacing system for spinal cord injury patients on a ventilator. The device, CE marked in 2007 and FDA-approved in 2008, uses four electrodes implanted under the skin to electrically stimulate the diaphragm. It has also been approved in the U.S. to treat hypoventilation associated with Lou Gehrig's disease. Synapse intends to apply the new funding to expedite its next trial. Release